Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity
First Claim
Patent Images
1. A method of upregulating a function of and/or the expression of a Filaggrin (FLG) polynucleotide in patient cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one single-stranded antisense oligonucleotide of 15 to 25 nucleotides in length or a siRNA oligonucleotide of 19 to 25 nucleotides in length wherein said at least one is 100% complementary with and specifically hybridizes to a 15 to 25 nucleotide region or, in the case of siRNA, to a 19 to 25 nucleotide non-overlapping sequence of SEQ ID NO;
2;
thereby upregulating a function of and/or the expression of the Filaggrin (FLG) polynucleotide in patient cells or tissues in vivo or in vitro.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to antisense oligonucleotides and/or compounds that modulate the expression of and/or function of Filaggrin (FLG), in particular, by targeting natural antisense polynucleotides of Filaggrin (FLG). The invention also relates to the identification of these antisense oligonucleotides and/or compounds and their use in treating diseases and disorders associated with the expression of FLG.
203 Citations
15 Claims
-
1. A method of upregulating a function of and/or the expression of a Filaggrin (FLG) polynucleotide in patient cells or tissues in vivo or in vitro comprising:
contacting said cells or tissues with at least one single-stranded antisense oligonucleotide of 15 to 25 nucleotides in length or a siRNA oligonucleotide of 19 to 25 nucleotides in length wherein said at least one is 100% complementary with and specifically hybridizes to a 15 to 25 nucleotide region or, in the case of siRNA, to a 19 to 25 nucleotide non-overlapping sequence of SEQ ID NO;
2;
thereby upregulating a function of and/or the expression of the Filaggrin (FLG) polynucleotide in patient cells or tissues in vivo or in vitro.- View Dependent Claims (11)
-
2. A method of upregulating a function of and/or the expression of a Filaggrin (FLG) polynucleotide in patient cells or tissues in vivo or in vitro comprising:
contacting said cells or tissues with at least one single-stranded antisense oligonucleotide of 15 to 21 nucleotides in length that is 100% complementary with, targets and specifically hybridizes to a region of a natural antisense RNA polynucleotide of the Filaggrin (FLG) polynucleotide having sequence identity to SEQ ID NO;
2;
thereby upregulating a function of and/or the expression of the Filaggrin (FLG) polynucleotide in patient cells or tissues in vivo or in vitro.- View Dependent Claims (3, 4, 5, 6, 7, 8, 9, 10)
-
12. A method of upregulating a function of and/or the expression of a Filaggrin (FLG) gene in mammalian cells or tissues in vivo or in vitro comprising:
contacting said cells or tissues with at least one short interfering RNA (siRNA) oligonucleotide 19 to 23 nucleotides in length, said at least one siRNA oligonucleotide is 100% complementary with and specific for a natural antisense polynucleotide of a Filaggrin (FLG) polynucleotide selected from SEQ ID NO;
2, wherein said at least one siRNA oligonucleotide specifically hybridizes to a non-overlapping, complementary region of said natural antisense polynucleotide of the Filaggrin (FLG) polynucleotide; and
, upregulates a function of and/or the expression of Filaggrin (FLG) in mammalian cells or tissues in vivo or in vitro.
-
13. A method of treating a disease associated with at least one Filaggrin (FLG) polynucleotide and/or at least one encoded product thereof having SEQ ID NO:
- 1, comprising;
administering to a patient a therapeutically effective dose of at least one (i) single-stranded antisense oligonucleotide of 15 to 25 nucleotides in length that specifically hybridizes to a natural antisense polynucleotide of said at least one Filaggrin (FLG) polynucleotide or (ii) a siRNA of 19 to 25 nucleotides in length that specifically hybridizes to a non-overlapping region of said at least one Filaggrin (FLG) polynucleotide and upregulates expression of said at least one Filaggrin (FLG) polynucleotide;
thereby treating the disease associated with the at least one Filaggrin (FLG) polynucleotide and/or at least one encoded product thereof wherein said disease associated with the at least one Filaggrin (FLG) polynucleotide is selected from;
psoriasis, atopic dermatitis (AD), ichthyosis vulgaris or eczema. - View Dependent Claims (14, 15)
- 1, comprising;
Specification